WEBINAR

Lost in Translation – An In Vitro Solution to Improve Early Clinical Success

Summary of webinar:
The immune system is interwoven into all human biological systems and has become increasingly important both as a therapeutic target and as a therapeutic modality. Delineation of the underlying immunobiology of health and disease states often utilizes the study of animal models, which may provide great insight into key immunological mechanisms. However, these may also highlight the biological divide that exists between species and the subsequent challenge in translating these findings from animals to humans further along the development pipeline.
As the cost and complexity of clinical trials continues to increase, the importance of ensuring that early stage clinical studies are suitable and provide value to the overall development pipeline has increased.

objectives

In this live webinar, we will discuss:
  • Limitations of current animal models in translating immunobiology from animals to humans
  • Complexity of the Immune System
  • An alternative, in vitro translational platform for early stage clinical trials which
    1. Allow early insight into the efficacy, safety and mechanism of action of a therapy.
    2. Prioritize and refine therapeutic indications by assessing efficacy.
    3. Focus the biomarker panels and analytical techniques to those which will generate the most significant clinical and biological insights.
    4. Benchmark the candidate drug against other drug leads and commercially available competitor products.
  • Applications of the platform.

Speaker

Dr. Justin Devine
Chief Medical Officer
Justin is a medical doctor, immunologist and pharmacologist and a co-founder of Synexa. His primary focus is to understand our clients’ objectives in new drug development by designing biomarker strategies to bring real insight to the challenges of clinical development. Justin has a very deep understanding of the role that biomarkers and pharmacogenetics play in under-standing the performance of a candidate drug. He is particularly passionate about improving the drug development process by bringing innovative approaches to early phase research, including new ideas in translational medicine, bioinformatics and artificial intelligence.
Session 1:
Tuesday, Nov 24, 2020 – 4:00 PM
(9:00 AM ET; 3:00 PM CET)
Session 2:
Tuesday, Nov 24, 2020 – 7:00 PM
(9:00 AM PT)
Webinars will be available for on-demand viewing after the event.
Follow our LinkedIn page to stay up to date and for more events like this in the future.